IL108681A0 - Influenza vaccine compositions - Google Patents

Influenza vaccine compositions

Info

Publication number
IL108681A0
IL108681A0 IL10868194A IL10868194A IL108681A0 IL 108681 A0 IL108681 A0 IL 108681A0 IL 10868194 A IL10868194 A IL 10868194A IL 10868194 A IL10868194 A IL 10868194A IL 108681 A0 IL108681 A0 IL 108681A0
Authority
IL
Israel
Prior art keywords
vaccine compositions
influenza vaccine
influenza
compositions
vaccine
Prior art date
Application number
IL10868194A
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL108681A0 publication Critical patent/IL108681A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL10868194A 1993-02-19 1994-02-17 Influenza vaccine compositions IL108681A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US11575093A 1993-09-01 1993-09-01

Publications (1)

Publication Number Publication Date
IL108681A0 true IL108681A0 (en) 1994-05-30

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10868194A IL108681A0 (en) 1993-02-19 1994-02-17 Influenza vaccine compositions

Country Status (9)

Country Link
EP (1) EP0684838A1 (en)
AP (1) AP431A (en)
AU (1) AU6141094A (en)
CA (1) CA2156525A1 (en)
IL (1) IL108681A0 (en)
MA (1) MA23118A1 (en)
MX (1) MX9401225A (en)
SI (1) SI9400085A (en)
WO (1) WO1994019013A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (en) 1999-02-11 2001-07-25 Immuno Ag INACTIVATED INFLUENZA VIRUS VACCINE FOR NASAL OR ORAL APPLICATION
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE60239594D1 (en) * 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION
AR032575A1 (en) * 2001-02-23 2003-11-12 Smithkline Beecham Biolog USE OF AN ANTIGEN FLU PREPARATION FOR THE MANUFACTURE OF AN INTRADERMIC VACCINE OF THE FLU AND PHARMACEUTICAL CASE THAT INCLUDES SUCH VACCINE
GB2386072A (en) * 2001-04-27 2003-09-10 Becton Dickinson Co Novel vaccine
RS51721B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Decreasing potential iatrogenic risks associated with influenza vaccines
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
HUE027837T2 (en) 2005-03-23 2016-11-28 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
MX2009000660A (en) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Influenza vaccine.
BRPI0721393B8 (en) * 2007-03-22 2022-09-06 Fund Butantan method to obtain monophosphorylated lipid from bordetella pertussis as a by-product of cellular pertussis vaccine production
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2268309B1 (en) * 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CA2812135A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
SG11201607404PA (en) * 2014-03-25 2016-10-28 Government Of The Us Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
EP3820510A4 (en) 2018-07-10 2022-05-04 Seqirus Pty Ltd Removal of agglomerates
CN112361796A (en) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 Crushing and drying device used before straw recovery and storage
CN114989269B (en) * 2022-06-30 2023-09-19 天康制药股份有限公司 Bovine akabane immunogenicity antigen and vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
DK425789A (en) * 1988-08-31 1990-03-01 Smithkline Beecham Corp VACCINAL POLYPEPTIDES
AU654970B2 (en) * 1990-09-28 1994-12-01 Smithkline Beecham Biologicals (Sa) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
WO1992011291A1 (en) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
FR2671974A1 (en) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc INFLUENZA VACCINE COMPOSITION WITH SYNERGISTIC EFFECT, CONTAINING AS AN ADDITIVE TO INFLUENZA VIRUS CORE.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2143716T3 (en) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS.

Also Published As

Publication number Publication date
AU6141094A (en) 1994-09-14
SI9400085A (en) 1994-09-30
MA23118A1 (en) 1994-10-01
MX9401225A (en) 1994-08-31
EP0684838A1 (en) 1995-12-06
CA2156525A1 (en) 1994-09-01
AP431A (en) 1995-11-15
WO1994019013A1 (en) 1994-09-01
AP9400621A0 (en) 1994-04-30

Similar Documents

Publication Publication Date Title
IL109056A0 (en) Vaccine compositions
AP9300502A0 (en) Vaccine compositions
AP9400621A0 (en) Influenza vaccine compositions
IL118004A0 (en) Vaccine compositions
GB9503863D0 (en) Vaccine compositions
AU1308495A (en) Influenza vaccine
IL108915A0 (en) Polynucleotide vaccine against influenza virus
GR990300017T1 (en) Influenza vaccine
ZA946262B (en) Pharmaceutical compositions
IL128318A0 (en) Vaccine composition against malaria
IL110201A0 (en) Novel pharmaceutical compositions
GB9401787D0 (en) Vaccine compositions
GB9326425D0 (en) Vaccine compositions
GB9317504D0 (en) Pharmaceutical compositions
HU9401771D0 (en) Pharmaceutical compositions cintaining ipsapiron
GB9614618D0 (en) Vaccine compositions
GB9306029D0 (en) Vaccine compositions
GB9320454D0 (en) Vaccine compositions
GB9403417D0 (en) Vaccine compositions
GB9416097D0 (en) Vaccine compositions
GB9425980D0 (en) Vaccine compositions
GB9601739D0 (en) Vaccine Compositions
ZA947878B (en) Pharmaceutical compositions
IL94510A0 (en) Influenza vaccine
GB9323754D0 (en) Vaccine